Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
AstraZeneca
McKinsey
Express Scripts
Colorcon

Last Updated: June 26, 2022

CLINICAL TRIALS PROFILE FOR FLUDEOXYGLUCOSE F-18


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Fludeoxyglucose F-18

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00001568 ↗ Phase II Study of the Role of Anti-CEA Antibody Immunoscintigraphy & Positron Emission Tomography in the Localization of Recurrent Colorectal Carcinoma in Patients With Rising Serum CEA Levels in the Absence of Imageable Disease by Conventional Moda Completed National Cancer Institute (NCI) Phase 2 1997-02-01 Positron Emission Tomography (PET scanning) is performed using a total dose of less than 50 mRad per patient visit. Fludeoxyglucose F 18 (FDG) is injected intravenously over 2 min. Initial dynamic images will be obtained over the heart. Emission imaging will work from the midcervical region down to the perineal region. For CEA scanning, radiolabeled antibody, arcitumomab (IMMU-4), is injected intravenously over 5 min. A single photon emission computed tomography (SPECT) transmission scan is performed over the same regions as the emission scans. Total dose from transmission scans should be no more than 20 mRad per patient visit. Patients then undergo exploratory laparotomy performed by two surgeons, one blinded to the results of the CEA-Scan and PET scan. At the completion of all exploration, all identified disease is biopsied for pathologic analysis and any resectable disease is removed. Patients are followed every 3 months for 1 year, every 6 months for the second year, and then after 3 years.
NCT00004152 ↗ PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma Completed National Cancer Institute (NCI) Phase 2 1999-02-01 RATIONALE: Diagnostic procedures may improve the ability to detect metastatic melanoma and to determine the extent of disease. PURPOSE: Phase II trial to evaluate the effectiveness of PET and CT scans to detect metastatic disease in patients who have stage III or stage IV melanoma.
NCT00004152 ↗ PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma Completed Memorial Sloan Kettering Cancer Center Phase 2 1999-02-01 RATIONALE: Diagnostic procedures may improve the ability to detect metastatic melanoma and to determine the extent of disease. PURPOSE: Phase II trial to evaluate the effectiveness of PET and CT scans to detect metastatic disease in patients who have stage III or stage IV melanoma.
NCT00004867 ↗ Positron Emission Tomography in Determining Stage of Esophageal Cancer Completed National Cancer Institute (NCI) N/A 1999-11-01 RATIONALE: Imaging procedures such as positron emission tomography may improve the ability to determine the stage of esophageal cancer. PURPOSE: This clinical trial is studying how well fludeoxyglucose F 18 positron emission tomography determines tumor stage in patients with esophageal cancer.
NCT00004867 ↗ Positron Emission Tomography in Determining Stage of Esophageal Cancer Completed Alliance for Clinical Trials in Oncology N/A 1999-11-01 RATIONALE: Imaging procedures such as positron emission tomography may improve the ability to determine the stage of esophageal cancer. PURPOSE: This clinical trial is studying how well fludeoxyglucose F 18 positron emission tomography determines tumor stage in patients with esophageal cancer.
NCT00004891 ↗ PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During Surgery Completed National Cancer Institute (NCI) N/A 1999-09-01 RATIONALE: Diagnostic procedures, such as PET and CT scans, may improve the ability to detect the extent of locally advanced primary rectal cancer and may also help to measure a patient's response to treatment. PURPOSE: This clinical trial is studying how well PET and CT scans detect residual or metastatic disease in patients with locally advanced primary rectal cancer that can be removed during surgery.
NCT00004891 ↗ PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During Surgery Completed Memorial Sloan Kettering Cancer Center N/A 1999-09-01 RATIONALE: Diagnostic procedures, such as PET and CT scans, may improve the ability to detect the extent of locally advanced primary rectal cancer and may also help to measure a patient's response to treatment. PURPOSE: This clinical trial is studying how well PET and CT scans detect residual or metastatic disease in patients with locally advanced primary rectal cancer that can be removed during surgery.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Fludeoxyglucose F-18

Condition Name

Condition Name for Fludeoxyglucose F-18
Intervention Trials
Lymphoma 15
Lung Cancer 9
Breast Cancer 7
Sarcoma 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Fludeoxyglucose F-18
Intervention Trials
Carcinoma 27
Lymphoma 25
Lung Neoplasms 21
Sarcoma 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Fludeoxyglucose F-18

Trials by Country

Trials by Country for Fludeoxyglucose F-18
Location Trials
Canada 57
Australia 8
Puerto Rico 6
Korea, Republic of 5
New Zealand 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Fludeoxyglucose F-18
Location Trials
California 58
Maryland 53
Ohio 49
Illinois 45
New York 44
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Fludeoxyglucose F-18

Clinical Trial Phase

Clinical Trial Phase for Fludeoxyglucose F-18
Clinical Trial Phase Trials
Phase 4 3
Phase 3 15
Phase 2/Phase 3 5
[disabled in preview] 135
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Fludeoxyglucose F-18
Clinical Trial Phase Trials
Completed 69
Active, not recruiting 35
Recruiting 25
[disabled in preview] 42
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Fludeoxyglucose F-18

Sponsor Name

Sponsor Name for Fludeoxyglucose F-18
Sponsor Trials
National Cancer Institute (NCI) 120
University of Washington 8
NRG Oncology 7
[disabled in preview] 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Fludeoxyglucose F-18
Sponsor Trials
Other 150
NIH 122
Industry 26
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Dow
Merck
Baxter
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.